Health Technology · Pharmaceuticals: Major · NSE: MEDICAPQ · data 2026-10-09
Medi-Caps Ltd.
Health check: Weak (2.2/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹25.5
Market cap
₹32 cr
P/E
—
P/B
—
ROE
-2.6%
ROCE
-9.5%
Debt / equity
0
Dividend yield
0.00%
1-year return
-2.7%
52-week high
₹36.8
52-week low
₹20.33
Operating margin
-77.2%
Growth
| Revenue (last 12 months) | ₹13 cr |
| Net profit (last 12 months) | ₹-2 cr |
| Sales growth, 3 years (yearly) | -36.9% |
| Profit growth, 3 years (yearly) | — |
Similar companies
Vivimed Labs Limited (VIVIMEDLAB) · Mangalam Drugs & Organics Ltd. (MANGALAM) · Biofil Chemicals & Pharmaceuticals Ltd. (BIOFILCHEM) · Medicamen Organics Ltd. (MEDIORG) · Lasa Supergenerics Ltd. (LASA)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open MEDICAPQ in NSE Scanner →